Table 4.
Clinicopathological characteristics of cytotoxic molecule‐positive, Epstein–Barr virus‐negative cutaneous T‐cell lymphoma, unspecified subtypes
| Characteristic | CD8+ | γ/δ | α/β pleomorphic | P * | P ** | |||
|---|---|---|---|---|---|---|---|---|
| n | % | n | % | n | % | |||
| Total | 5 | 8 | 8 | |||||
| Sex (male/female) | 5/0 | 4/4 | 7/1 | 0.06 | 0.11 | |||
| Age (years), median (range) | 58 (28–79) | 58 (36–76) | 49 (29–81) | 0.77 | 0.96 | |||
| Performance status score 2–4 | 0 | 0 | 0 | 0 | 2 | 25 | 0.17 | |
| Clinical stage 3–4 | 0 | 0 | 2 | 25 | 1 | 13 | 0.22 | 0.52 |
| B symptoms | 0 | 0 | 3 | 38 | 4 | 50 | 0.12 | 0.61 |
| Case limited to the skin | 4 | 80 | 6 | 75 | 4 | 50 | 0.84 | 0.30 |
| Lymph node involvement | 1 | 20 | 1 | 13 | 4 | 50 | 0.72 | 0.11 |
| Bone marrow involvement | 0 | 0 | 1 | 13 | 0 | 0 | 0.41 | 0.30 |
| LDH higher than normal | 1 | 20 | 2 | 25 | 3 | 38 | 0.84 | 0.59 |
| International Prognostic Index, HI/H | 0 | 0 | 1 | 13 | 1 | 13 | 0.41 | |
| Prognostic Index for Peripheral T‐cell Lymphoma group 3–4 | 1 | 20 | 1 | 13 | 3 | 38 | 0.72 | 0.25 |
| Gross appearance | ||||||||
| Nodule | 4 | 80 | 5 | 63 | 5 | 63 | 0.51 | |
| Multiple nodules | 4 | 80 | 4 | 50 | 5 | 63 | 0.28 | 0.61 |
| Spontaneous regression | 4 | 80 | 1 | 13 | 1 | 13 | 0.01 | |
| Fatal course within 1 year of diagnosis | 0 | 0 | 2 | 25 | 1 | 13 | 0.22 | 0.52 |
| Death | 1 | 20 | 2 | 25 | 3 | 38 | 0.84 | 0.59 |
| Histology | ||||||||
| Subcutaneous involvement | 2 | 40 | 7 | 88 | 8 | 100 | 0.07 | 0.30 |
| Immunophenotype | ||||||||
| CD2 | 5 | 100 | 7 | 88 | 7 | 88 | 0.41 | |
| cyCD3 | 4/4 † | 100 | 6 | 75 | 8 | 100 | 0.27 | 0.13 |
| CD4 | 3 | 60 | 0 | 0 | 5 | 63 | 0.01 | 0.007 |
| CD5 | 4 | 80 | 4 | 50 | 4 | 50 | 0.28 | |
| CD7 | 2 | 40 | 2 | 25 | 4 | 50 | 0.28 | 0.30 |
| CD8 | 5 | 100 | 3 | 38 | 0 | 0 | 0.02 | 0.05 |
| CD25 | 3/4 | 75 | 4 | 50 | 7 | 88 | 0.41 | 0.11 |
| CD30 | 2 | 40 | 4 | 50 | 5 | 63 | 0.72 | 0.61 |
| CD45RO | 5 | 100 | 5 | 63 | 7 | 88 | 0.12 | 0.25 |
| CD56 | 0 | 0 | 4 | 50 | 1 | 13 | 0.06 | 0.11 |
| TCR‐β | 5 | 100 | 0 | 0 | 8 | 100 | 0.0001 | 0.0001 |
| T‐cell intracellular antigen‐1 | 5 | 100 | 6 | 75 | 5 | 63 | 0.27 | 0.31 |
| Granzyme B | 5 | 100 | 8 | 100 | 8 | 100 | ||
| Perforin | 3/4 † | 75 | 6 | 75 | 7 | 88 | 0.79 | |
| Polymerase chain reaction | ||||||||
| TCR gene rearrangements | 0 | 0 | 1/6 | 17 | 2/7 | 29 | 0.34 | 0.61 |
CD8+, epidermotoropic CD8+ T‐cell lymphoma; γ/δ, cutaneous γ/δ T‐cell lymphoma; α/β pleomorphic; cutaneous α/β pleomorphic T‐cell lymphoma; HI/H, high to intermediate risk/high risk; LDH, lactate dehydrogenase; TCR, T‐cell receptor.
*
Epidermotoropic CD8+ T‐cell lymphoma versus cutaneous γ/δ T‐cell lymphoma.
**
Cutaneous γ/δ T‐cell lymphoma versus cutaneous α/β pleomorphic T‐cell lymphoma.
†
The denominator represents the number of cases examined.